hV01 / ConVerd - LARVOL DELTA

A study to evaluate the safety and primary efficacy of the combination therapy of recombinant human IL-21 oncolytic vaccinia virus injection (hV01) and ready-to-use CAR-raNK cells (IBR854) in patients with advanced malignant solid tumors (ChiCTR) - P=N/A | N=5 | Completed | Sponsor: Xiamen Humanity Hospital; Xiamen Humanity Hospital

New trial • Gynecologic Cancers • Head and Neck Cancer • Liver Cancer • Oncology • Pancreatic Cancer • Sarcoma • Solid Tumor

A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors. (clinicaltrials.gov) - P=N/A | N=24 | Recruiting | Sponsor: Hangzhou Converd Co., Ltd.

New trial • Solid Tumor

Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Hangzhou Converd Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Jun 2025 ➔ Oct 2025

Enrollment closed • Trial primary completion date • Oncology • Solid Tumor

Combination therapy of oncolytic vaccinia virus and PD-1 inhibitor in advanced solid tumors (ChiCTR) - P=N/A | N=24 | Not yet recruiting | Sponsor: Xiamen Humanity Hospital; Xiamen Humanity Hospital

New trial • Solid Tumor

Phase I study of hV01, a recombinant human IL-21-expressing oncolytic vaccinia virus, as monotherapy in advanced solid tumors. (ASCO 2025) - P1 | "Single-dosing of hV01 per treatment cycle was well tolerated and safe. hV01 i.t. injection demonstrated primary efficacy in patients with advanced tumors. The data support further study of multiple-dosing regimens and future trials evaluating the benefits of combining hV01 with other antitumor therapies."

Metastases • Monotherapy • Oncolytic virus • P1 data • Anemia • Head and Neck Cancer • Liposarcoma • Nasopharyngeal Carcinoma • Oncology • Sarcoma • Solid Tumor • Spindle Cell Sarcoma • IL21

Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Hangzhou Converd Co., Ltd. | Trial primary completion date: Mar 2025 ➔ Jun 2025

Trial primary completion date • Oncology • Solid Tumor

Safety of Recombinant Human IL-21 Oncolytic Vaccinia Virus Injection（hV01) in Advanced Tumors (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Hangzhou Converd Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncolytic virus • Gastrointestinal Cancer • Oncology • Solid Tumor • IL21